These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8427039)

  • 1. Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge.
    Niedrig M; Gregersen JP; Fultz PN; Bröker M; Mehdi S; Hilfenhaus J
    Vaccine; 1993; 11(1):67-74. PubMed ID: 8427039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.
    Gibbs CJ; Peters R; Gravell M; Johnson BK; Jensen FC; Carlo DJ; Salk J
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3348-52. PubMed ID: 2014254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
    Barrett N; Eder G; Dorner F
    Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.
    Arthur LO; Bess JW; Waters DJ; Pyle SW; Kelliher JC; Nara PL; Krohn K; Robey WG; Langlois AJ; Gallo RC
    J Virol; 1989 Dec; 63(12):5046-53. PubMed ID: 2555541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice.
    Alipour S; Mahdavi A; Abdoli A
    Pathog Dis; 2017 Mar; 75(2):. PubMed ID: 28175274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
    Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
    Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-dependent cellular cytotoxicity against HIV-1 in sera of immunized chimpanzees.
    Belo M; Yagello M; Girard M; Greenlee R; Deslandres A; Barré-Sinoussi F; Gluckman JC
    AIDS; 1991 Feb; 5(2):169-76. PubMed ID: 2031689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.
    el-Amad Z; Murthy KK; Higgins K; Cobb EK; Haigwood NL; Levy JA; Steimer KS
    AIDS; 1995 Dec; 9(12):1313-22. PubMed ID: 8605050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.
    Girard M; van der Ryst E; Barré-Sinoussi F; Nara P; Tartaglia J; Paoletti E; Blondeau C; Jennings M; Verrier F; Meignier B; Fultz PN
    Virology; 1997 May; 232(1):98-104. PubMed ID: 9185593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
    Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
    Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model.
    Moss RB; Savary JR; Diveley JP; Jensen F; Carlo DJ
    Immunology; 2002 Aug; 106(4):549-53. PubMed ID: 12153518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
    Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.
    Natuk RJ; Lubeck MD; Chanda PK; Chengalvala M; Wade MS; Murthy SC; Wilhelm J; Vernon SK; Dheer SK; Mizutani S
    AIDS Res Hum Retroviruses; 1993 May; 9(5):395-404. PubMed ID: 8318268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys.
    Putkonen P; Nilsson C; Walther L; Ghavamzadeh L; Hild K; Broliden K; Biberfeld G; Thorstensson R
    J Med Primatol; 1994; 23(2-3):89-94. PubMed ID: 7966239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
    Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
    Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.
    Moss RB; Li L; Giermakowska WK; Lanza P; Turner JL; Wallace MR; Jensen FC; Richieri SP; Daigle AE; Theofan G; Carlo DJ
    J Hum Virol; 1998; 1(2):77-81. PubMed ID: 10195235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
    Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.